#USA #San Mateo #AI tools #Helix #GenoSphere

Helix's Groundbreaking Advances in Genomic Research

In a significant leap towards enhanced healthcare solutions, Helix, the leading enterprise genomics platform, has announced the triumph of surpassing 500,000 clinico-genomic records within its Helix GenoSphere™. This endeavor positions Helix as a forerunner in the field of genomic datasets, making it one of the largest collections of its kind globally.

Expanding the Dataset

The Helix GenoSphere has seen exponential growth, doubling in size every two years, and is on pace to exceed one million records within the next 18 months. Each record is a confluence of advanced Exome+® sequencing data and an extensive history of electronic health records (EHR) that average around 13 years, along with eight years of claims data, all amassed from 16 members of the Helix Research Network. This depth of information enables a comprehensive view of patient histories and clinical interactions over extensive periods.

AI-Driven Innovations

To accelerate the pace of discovery and research based on this vast database, Helix is introducing a suite of AI-powered tools, notably the new Cohort Builder. This tool allows researchers to swiftly construct and analyze specific clinico-genomic cohorts, addressing a critical bottleneck that often hampers research progress—the labor-intensive task of identifying suitable study populations.

Equipped with self-service capabilities, the Cohort Builder enables users to create targeted subsets derived from linked clinico-genomic data across various therapeutic domains including cardiometabolic and autoimmune disorders. This innovation not only enhances the speed at which researchers can generate insights but also allows for more flexible cohort creation, making research more manageable and efficient.

Insights from Helix’s Leadership

James Lu, M.D., Ph.D., CEO and co-founder of Helix, elaborated on the significance of the company's advancements, stating, "Researchers frequently face challenges related to data quality, scale, and the necessary technical resources to yield groundbreaking insights. With GenoSphere and our AI tools, we dramatically reduce the time needed to derive meaningful insights, combining intuitive data exploration with a vast repository of clinico-genomic data. This represents a momentous step in the journey to make genomic data actionable in various research areas."

Strategic Vision for the Future

The introduction of this new AI tool, paired with the milestone of accumulating over 500,000 clinico-genomic records, underscores Helix's commitment to fostering innovation in genomic research. The broader strategy entails harnessing AI to seamlessly integrate advanced analytics with scalable infrastructures to promote effective data discovery and research at scale.

This notable achievement exemplifies Helix's initiative to transition genomic insights from research applications into widespread clinical practice. As Helix continues to bolster its infrastructure and capabilities, the medical community can anticipate a future where genomic data plays a crucial role in driving personalized medicine and improving patient care.

To learn more about accessing Helix GenoSphere and see a demo of the new tools in action, you can reach out directly to Helix’s team via their official website.

About Helix

Helix stands at the forefront of enterprise genomics, empowering health systems and life science organizations to harness the potential of genomic insights. The Helix Research Network is distinguished as the world’s largest precision health network, designed to accelerate genomic discoveries and facilitate their transfer into clinical impact. For more in-depth information on Helix's initiatives, visit their website at www.helix.com.